Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction
Vivos received FDA IDE approval on July 2, enabling a first-in-human feasibility study at Mayo Clinic targeting non-resectable papillary thyroid carcinoma with an initial enrollment of five patients. The company's animal therapy segment expanded to 17 certified U.S. clinics treating over 200 animals, bolstered by new agreements in California and North Carolina, while domestic manufacturing validation nears completion.
Key figures
- Phase Of Trial
- Feasibility
- Us clinics
- 17
- Animals treated
- 200+
- Follow up months
- 24
- Initial patients
- 5
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.